Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.

@article{Hamid2017FinalAO,
  title={Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.},
  author={Omid Hamid and Igor Puzanov and Reinhard Dummer and Jacob Schachter and Adil I Daud and Dirk Schadendorf and Christian U. Blank and Lee Cranmer and Caroline Robert and Anna C Pavlick and R. Cabez{\'o}n Gonz{\'a}lez and F Stephen Hodi and Paolo Antonio Ascierto and April K. Salama and Kim A Margolin and Tara C. Gangadhar and Ziwen Wei and Scot W. Ebbinghaus and Nageatte Ibrahim and Antoni Ribas},
  journal={European journal of cancer},
  year={2017},
  volume={86},
  pages={
          37-45
        }
}
AIM To evaluate the protocol-specified final analysis of overall survival (OS) in the KEYNOTE-002 study (NCT01704287) of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory, advanced melanoma. METHODS In this randomised, phase II study, eligible patients had advanced melanoma with documented progression after two or more ipilimumab doses, previous BRAF or MEK inhibitor or both, if BRAFV600 mutant-positive. Patients were randomised to pembrolizumab 2 mg/kg or 10 mg/kg… CONTINUE READING

Figures, Tables, and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 21 CITATIONS

Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial

  • Journal for ImmunoTherapy of Cancer
  • 2019
VIEW 4 EXCERPTS
CITES RESULTS & BACKGROUND
HIGHLY INFLUENCED

Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody

Jiyun Lee, Su Jin Lee, +3 authors Jeeyun Lee
  • BMC Cancer
  • 2019
VIEW 2 EXCERPTS
CITES RESULTS & BACKGROUND

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 14 REFERENCES

Pembrolizumab versus Ipilimumab in Advanced Melanoma.

  • The New England journal of medicine
  • 2015
VIEW 1 EXCERPT

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2014